Decision of the Management Board amending budget No. 01, amending appropriations in budget 2024
Decision of the Management Board amending budget No. 01, amending appropriations in budget 2024
Decision of the Management Board amending budget No. 01, amending appropriations in budget 2024
Work plan for the Committee for Veterinary Medicinal Products (CVMP) Efficacy Working Party (EWP-V) 2024
Maximum residue limit (MRL) evaluation for biological substances - Scientific guideline
Plasmid DNA vaccines for veterinary use – Scientific guideline
Work plan for the Committee for Veterinary Medicinal Products (CVMP) Immunologicals Working Party (IWP) 2024
Precautionary measures to address potential risk of neurodevelopmental disorders in children born to men treated with valproate medicines
Clinical data publication
Summary of opinion: Apexxnar, 25/01/2024 Positive
Orphan designation: 5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride Treatment of adrenoleukodystrophy, 18/11/2016 Positive
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2024